A phase 2, randomized, double-blind, placebo-controlled, parallel group, multi-center study to evaluate the efficacy and safety of once daily administration of Chemokine CCR2/5 receptor antagonist (PF-04634817) in adults with type 2 diabetes and Overt Nephropathy.